AJANTPHARM Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > ajantpharm

Technical Analysis

Technical Strength: 2 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 45.1. According to RSI analysis, ajantpharm is technically weak. 1.0 AJANTPHARM RSI Chart
MACD (?) MACD: -2.75 and Signal Line: -1.65. According to MACD analysis, ajantpharm is technically weak. 2.0 AJANTPHARM MACD Chart
Simple Moving Average (?) Price just got below it's 50-day simple moving average which is a negative signal. Price just got below it's 20-day simple moving average which is a negative signal. According to simple moving average analysis, ajantpharm is facing resistance at 1.38e+03 and support level is at 1343.46. 2.0 AJANTPHARM Simple Moving Average Chart
Exponential Moving Average (?) Price just got below it's 20-day exponential moving average which is a negative signal. According to exponential moving average analysis, ajantpharm is in a strong downtrend. Major resistance levels are 1380.74, 1387.322, 1409.818. 1.0 AJANTPHARM Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.25. 5.0 AJANTPHARM Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, no levels identified. NA AJANTPHARM Fibonacci Retracement Chart
Average True Range (?) ATR: 34.7 NA AJANTPHARM Average True Range Chart
Average Directional Index (?) ADX is 7.28 which means AJANTPHARM is in a trading range and there is no trend. NA AJANTPHARM Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
April 20, 2018
Open Price 1383.95
High Price 1383.95
Low Price 1361.0
Close Price 1365.0
Absolute Change -20.2
Percentage Change -1.46%
Weekly Change 0%
Monthly Change -0.875%
Yearly Change -22.4%
52-week high 1780.0
52-week low 1120.05
Corporate Actions
ExDate Purpose
June 23, 2017 ANNUAL GENERAL MEETING
March 23, 2017 INT DIV RS 7/- PER SHARE
March 23, 2017 INTERIM DIVIDEND
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.718
Confidence in Beta2.11%
Market Capital Rs. 12010.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 43.76
TTM Price-to-Earnings (P/E) Ratio 31.2
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 20 April 2018: Deliverable Quantity:2.51e+04 NA AJANTPHARM Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 20 April 2018: Daily Volatility:0.2656 NA AJANTPHARM Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 20 April 2018: PCR_OI:0.248 PCR:0.314 NA AJANTPHARM PCR Chart
Option Pain (?) 20 April 2018: Max Pain:1350.0 NA AJANTPHARM Option Pain Chart
Premium (?) 20 April 2018 Premium: 1.85 Futures OI:738000.0 NA AJANTPHARM Premium Chart
Option_MAX_OI (?) 20 April 2018: Price:1365.0 Put with maximum OI:1350.0 Call with maximum OI:1450.0 NA AJANTPHARM Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
April 26, 2018 1366.85 738000.0 425.0 536.0 1365.0
May 31, 2018 1375.2 79500.0 109.0 197.0 1365.0

Announcements

April 04, 2018 Disc. under Reg.30 of SEBI (SAST) Reg.2011 Yogesh M. Agrawal has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
April 03, 2018 Disc. under Reg.30 of SEBI (SAST) Reg.2011 Yogesh M Agrawal along with Promoters/PAC has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
See all Announcements

Board Meetings

Date Meeting Date Purpose
January 16, 2018 January 25, 2018 Results To consider and approve inter-alia, Unaudited consolidated and standalone Financial Results of the Company for the third quarter ended December 31, 2017.
October 18, 2017 October 31, 2017 Results To consider and approve inter-alia, Unaudited consolidated and standalone Financial Results of the Company for the second quarter and half year ended September 30, 2017.
See all Board Meetings

AJANTPHARM is part of...

Index Weightage
NFTYMCAP50 NA

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 1333 Rs. 1347 Rs. 1356 Rs. 1370 Rs. 1379 Rs. 1393 Rs. 1402